From the Department of Psychiatry, Boston Medical Center, Boston University School of Medicine, Boston, MA (Dr. Rivas-Grajales); Department of Psychiatry, Division of Behavioral Neurology and Neuropsychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA (Drs. Barbour, Camprodon, Kritzer); Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA (Drs. Camprodon, Kritzer).
Harv Rev Psychiatry. 2023;31(3):114-123. doi: 10.1097/HRP.0000000000000366.
Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising alternative for the treatment of major depressive disorder (MDD), although its clinical effectiveness varies substantially. The effects of sex hormone fluctuations on cortical excitability have been identified as potential factors that can explain this variability. However, data on how sex hormone changes affect clinical response to rTMS is limited. To address this gap, we reviewed the literature examining the effects of sex hormones and hormonal treatments on transcranial magnetic stimulation (TMS) measures of cortical excitability. Results show that variations of endogenous estrogen, testosterone, and progesterone have modulatory effects on TMS-derived measures of cortical excitability. Specifically, higher levels of estrogen and testosterone were associated with greater cortical excitability, while higher progesterone was associated with lower cortical excitability. This highlights the importance of additional investigation into the effects of hormonal changes on rTMS outcomes and circuit-specific physiological variables. These results call for TMS clinicians to consider performing more frequent motor threshold (MT) assessments in patients receiving high doses of estrogen, testosterone, and progesterone in cases such as in vitro fertilization, hormone replacement therapy, and gender-affirming hormonal treatments. It may also be important to consider physiological hormonal fluctuations and their impact on depressive symptoms and the MT when treating female patients with rTMS.
重复经颅磁刺激(rTMS)已成为治疗重度抑郁症(MDD)的一种很有前途的替代方法,但它的临床疗效差异很大。性激素波动对皮质兴奋性的影响已被确定为可以解释这种变异性的潜在因素。然而,关于性激素变化如何影响 rTMS 临床反应的数据有限。为了解决这一差距,我们回顾了检查性激素和激素治疗对经颅磁刺激(TMS)皮质兴奋性测量影响的文献。结果表明,内源性雌激素、睾酮和孕酮的变化对 TMS 衍生的皮质兴奋性测量有调节作用。具体来说,较高的雌激素和睾酮水平与较高的皮质兴奋性相关,而较高的孕酮水平与较低的皮质兴奋性相关。这突出表明需要进一步研究激素变化对 rTMS 结果和特定于电路的生理变量的影响。这些结果呼吁 TMS 临床医生考虑在接受高剂量雌激素、睾酮和孕酮的患者中更频繁地进行运动阈值(MT)评估,例如在体外受精、激素替代治疗和性别肯定激素治疗中。在使用 rTMS 治疗女性患者时,考虑生理性激素波动及其对抑郁症状和 MT 的影响也可能很重要。